- Home
- FLYE vs RDHL Comparison
FLYE vs RDHL Comparison
Compare FLYE & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- RDHL
- Stock Information
- Founded
- FLYE 2018
- RDHL 2009
- Country
- FLYE United States
- RDHL Israel
- Employees
- FLYE N/A
- RDHL N/A
- Industry
- FLYE Aerospace
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- RDHL Health Care
- Exchange
- FLYE Nasdaq
- RDHL Nasdaq
- Market Cap
- FLYE 15.5M
- RDHL 13.1M
- IPO Year
- FLYE 2024
- RDHL N/A
- Fundamental
- Price
- FLYE $0.59
- RDHL $8.10
- Analyst Decision
- FLYE
- RDHL
- Analyst Count
- FLYE 0
- RDHL 0
- Target Price
- FLYE N/A
- RDHL N/A
- AVG Volume (30 Days)
- FLYE 174.1K
- RDHL 23.8K
- Earning Date
- FLYE 11-10-2024
- RDHL 10-22-2024
- Dividend Yield
- FLYE N/A
- RDHL N/A
- EPS Growth
- FLYE 1.84
- RDHL N/A
- EPS
- FLYE 0.06
- RDHL N/A
- Revenue
- FLYE $32,236,745.00
- RDHL $3,707,000.00
- Revenue This Year
- FLYE N/A
- RDHL $224.90
- Revenue Next Year
- FLYE N/A
- RDHL $82.69
- P/E Ratio
- FLYE $11.04
- RDHL N/A
- Revenue Growth
- FLYE 36.51
- RDHL N/A
- 52 Week Low
- FLYE $0.51
- RDHL $6.80
- 52 Week High
- FLYE $7.62
- RDHL $82.00
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- RDHL 41.48
- Support Level
- FLYE N/A
- RDHL $7.95
- Resistance Level
- FLYE N/A
- RDHL $8.25
- Average True Range (ATR)
- FLYE 0.00
- RDHL 0.37
- MACD
- FLYE 0.00
- RDHL -0.05
- Stochastic Oscillator
- FLYE 0.00
- RDHL 11.90
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.